BridgeBio Pharma, Inc., a biopharmaceutical company focusing on genetic diseases, announced that its compensation committee approved equity grants in the form of restricted stock units (RSUs) to new employees under its Amended and Restated 2019 Inducement Equity Plan. On various dates in July, August, and September 2025, RSU grants were given to new employees, totaling 33,684 shares to 13 employees, 32,145 shares to 16 employees, and 73,991 shares to 20 employees. Additionally, on June 6, 2025, RSU grants of 98,348 shares were approved for 25 new employees. These RSUs will vest gradually over time, with one-fourth of the shares vesting in August 2026 and the remaining shares vesting quarterly over the next three years, contingent on continued employment with the company.